Drugs / CEP1347
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00040404 | Mar 2002 → Aug 2005 | Parkinson disease | Cephalon | Terminated | Missed primary |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEP1347 | “CEP1347 25mg, a K252a derivative, retains neuroprotective properties” NCT00040404 ↗ |
| Known as | 3,9-bis((ethylthio)methyl)-k-252a | ChEMBL registry synonym — accepted as the source's own label CHEMBL290352 ↗ |
| Known as | KT-1575 | ChEMBL registry synonym — accepted as the source's own label CHEMBL290352 ↗ |
| Known as | KT-7515 | ChEMBL registry synonym — accepted as the source's own label CHEMBL290352 ↗ |
| Action | Inhibit | “CEP-1347 inhibits mixed lineage kinases that activate apoptotic pathways implicated in the pathogenesis of Parkinson disease (PD).” PMID 17881719 ↗ Sep 20075“Mitogen-activated protein kinase kinase kinase 11 inhibitor” CHEMBL290352 ↗ “Mitogen-activated protein kinase kinase kinase 12 inhibitor” CHEMBL290352 ↗ “Mitogen-activated protein kinase kinase kinase 10 inhibitor” CHEMBL290352 ↗ “Mitogen-activated protein kinase kinase kinase 13 inhibitor” CHEMBL290352 ↗ “Mitogen-activated protein kinase kinase kinase 9 inhibitor” CHEMBL290352 ↗ |
| Modality | Small molecule | — CHEMBL290352 ↗ |
| Target | MAP3K10 | “Mitogen-activated protein kinase kinase kinase 10 inhibitor” CHEMBL290352 ↗ |
| Target | MAP3K11 | “Mitogen-activated protein kinase kinase kinase 11 inhibitor” CHEMBL290352 ↗ |
| Target | MAP3K12 | “Mitogen-activated protein kinase kinase kinase 12 inhibitor” CHEMBL290352 ↗ |
| Target | MAP3K13 | “Mitogen-activated protein kinase kinase kinase 13 inhibitor” CHEMBL290352 ↗ |
| Target | MAP3K9 | “Mitogen-activated protein kinase kinase kinase 9 inhibitor” CHEMBL290352 ↗ |